Pfizer starts study of oral drug for preventing COVID-19


Pfizer has started testing an oral antiviral pill aimed at preventing COVID-19 infections, the pharmaceutical company announced Monday.
The drug, PF-07321332, is designed to block the main enzyme the coronavirus needs to multiply, Pfizer said. PF-07321332 will be co-administered with a small dose of ritonavir, an antiviral that is used in combination with other medications to treat HIV.
"If successful, we believe this therapy could help stop the virus early — before it has had a chance to replicate extensively — potentially preventing symptomatic disease in those who have been exposed and inhibiting the onset of infection in others," Mikael Dolsten, Pfizer's chief scientific officer and president of worldwide research, development, and medical, said in a statement.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
This antiviral could not only help treat people who will not get vaccinated against COVID-19, but would also be beneficial in countries where they expect it will take several years to get all residents fully vaccinated, Axios notes.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Catherine Garcia has worked as a senior writer at The Week since 2014. Her writing and reporting have appeared in Entertainment Weekly, The New York Times, Wirecutter, NBC News and "The Book of Jezebel," among others. She's a graduate of the University of Redlands and the Columbia University Graduate School of Journalism.
-
What to know before turning to AI for financial advice
the explainer It can help you crunch the numbers — but it might also pocket your data
-
Book reviews: 'The Headache: The Science of a Most Confounding Affliction—and a Search for Relief' and 'Tonight in Jungleland: The Making of Born to Run'
Feature The search for a headache cure and revisiting Springsteen's 'Born to Run' album on its 50th anniversary
-
Keith McNally' 6 favorite books that have ambitious characters
Feature The London-born restaurateur recommends works by Leo Tolstoy, John le Carré, and more
-
Rabbits with 'horns' sighted across Colorado
speed read These creatures are infected with the 'mostly harmless' Shope papilloma virus
-
Lithium shows promise in Alzheimer's study
Speed Read Potential new treatments could use small amounts of the common metal
-
Scientists discover cause of massive sea star die-off
Speed Read A bacteria related to cholera has been found responsible for the deaths of more than 5 billion sea stars
-
'Thriving' ecosystem found 30,000 feet undersea
Speed Read Researchers discovered communities of creatures living in frigid, pitch-black waters under high pressure
-
New York plans first nuclear plant in 36 years
Speed Read The plant, to be constructed somewhere in upstate New York, will produce enough energy to power a million homes
-
Dehorning rhinos sharply cuts poaching, study finds
Speed Read The painless procedure may be an effective way to reduce the widespread poaching of rhinoceroses
-
Breakthrough gene-editing treatment saves baby
speed read KJ Muldoon was healed from a rare genetic condition
-
Sea lion proves animals can keep a beat
speed read A sea lion named Ronan beat a group of college students in a rhythmic dance-off, says new study